Maat Pharma SA
MaaT Pharma SA, a late-stage clinical company, engages in the development of gut microbiome-driven therapies to modulate the immune system and improve cancer survival. Its products pipeline includes MaaT013, that is in pivotal phase 3 clinical trial for the treatment of acute graft versus host diseases with gastrointestinal involvement; MaaT033, which is in phase 2b clinical trial for the improve… Read more
Maat Pharma SA (MAAT) - Net Assets
Latest net assets as of June 2025: €8.29 Million EUR
Based on the latest financial reports, Maat Pharma SA (MAAT) has net assets worth €8.29 Million EUR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€48.88 Million) and total liabilities (€40.58 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €8.29 Million |
| % of Total Assets | 16.97% |
| Annual Growth Rate | 10.11% |
| 5-Year Change | -35.14% |
| 10-Year Change | N/A |
| Growth Volatility | 184.15 |
Maat Pharma SA - Net Assets Trend (2017–2024)
This chart illustrates how Maat Pharma SA's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Maat Pharma SA (2017–2024)
The table below shows the annual net assets of Maat Pharma SA from 2017 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €10.34 Million | -49.50% |
| 2023-12-31 | €20.47 Million | -23.67% |
| 2022-12-31 | €26.81 Million | -32.73% |
| 2021-12-31 | €39.86 Million | +150.08% |
| 2020-12-31 | €15.94 Million | +449.11% |
| 2019-12-31 | €-4.57 Million | -459.73% |
| 2018-12-31 | €1.27 Million | -75.91% |
| 2017-12-31 | €5.27 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Maat Pharma SA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1930413900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €1.40 Million | 13.53% |
| Other Components | €35.24 Million | 340.96% |
| Total Equity | €10.34 Million | 100.00% |
Maat Pharma SA Competitors by Market Cap
The table below lists competitors of Maat Pharma SA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Taicera Enterprise Co
VN:TCR
|
$4.27 Million |
|
MainStreetChamber Holdings Inc.
PINK:MSCH
|
$4.27 Million |
|
Kumpulan H & L High-Tech Bhd
KLSE:7033
|
$4.27 Million |
|
RPCG PCL F
F:R4Q
|
$4.27 Million |
|
Carolina Rush Corporation
V:RUSH
|
$4.27 Million |
|
EPS Bio Technology Corp.
TWO:4183
|
$4.27 Million |
|
Living Cell Technologies Limited
PINK:LVCLF
|
$4.27 Million |
|
Fresh Grapes LLC
NYSE MKT:VINE
|
$4.27 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Maat Pharma SA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 20,466,000 to 10,336,000, a change of -10,130,000 (-49.5%).
- Net loss of 28,904,000 reduced equity.
- Share repurchases of 17,258,000 reduced equity.
- New share issuances of 17,276,000 increased equity.
- Other factors increased equity by 18,756,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-28.90 Million | -279.64% |
| Share Repurchases | €17.26 Million | -166.97% |
| Share Issuances | €17.28 Million | +167.14% |
| Other Changes | €18.76 Million | +181.46% |
| Total Change | €- | -49.50% |
Book Value vs Market Value Analysis
This analysis compares Maat Pharma SA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 8.87x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 1.38x to 8.87x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €5.10 | €7.02 | x |
| 2018-12-31 | €1.23 | €7.02 | x |
| 2019-12-31 | €-22.11 | €7.02 | x |
| 2020-12-31 | €77.19 | €7.02 | x |
| 2021-12-31 | €16.43 | €7.02 | x |
| 2022-12-31 | €2.71 | €7.02 | x |
| 2023-12-31 | €1.80 | €7.02 | x |
| 2024-12-31 | €0.79 | €7.02 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Maat Pharma SA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -279.64%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -898.76%
- • Asset Turnover: 0.08x
- • Equity Multiplier: 3.72x
- Recent ROE (-279.64%) is below the historical average (-114.35%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -73.24% | -3529.47% | 0.01x | 1.76x | €-4.39 Million |
| 2018 | -358.23% | -509.64% | 0.15x | 4.64x | €-4.67 Million |
| 2019 | 0.00% | -7443.12% | 0.01x | 0.00x | €-6.19 Million |
| 2020 | -33.57% | 0.00% | 0.00x | 1.52x | €-6.94 Million |
| 2021 | -22.63% | -927.88% | 0.02x | 1.24x | €-13.00 Million |
| 2022 | -51.15% | -958.95% | 0.03x | 1.67x | €-16.39 Million |
| 2023 | -96.34% | -884.96% | 0.05x | 2.10x | €-21.76 Million |
| 2024 | -279.64% | -898.76% | 0.08x | 3.72x | €-29.94 Million |
Industry Comparison
This section compares Maat Pharma SA's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $11,397,324
- Average return on equity (ROE) among peers: -51.25%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Maat Pharma SA (MAAT) | €8.29 Million | -73.24% | 4.89x | $4.27 Million |
| Abionyx Pharma SA (ABNX) | $8.89 Million | -56.01% | 1.06x | $71.47 Million |
| Abivax SA (ABVX) | $56.72 Million | -25.23% | 0.07x | $3.88 Billion |
| Adocia (ADOC) | $-6.91 Million | 0.00% | 0.00x | $84.43 Million |
| Aelis Farma SA (AELIS) | $898.00K | 63.92% | 30.53x | $5.17 Million |
| Acticor Biotech SAS (ALACT) | $-4.04 Million | 0.00% | 0.00x | $2.13 Million |
| NicOx S.A. (ALCOX) | $21.41 Million | -97.51% | 1.47x | $28.49 Million |
| Advicenne (ALDVI) | $-1.67 Million | 0.00% | 0.00x | $15.34 Million |
| ALGAE (ALGAE) | $32.76 Million | -39.31% | 0.56x | $30.55 Million |
| Genoway (ALGEN) | $5.23 Million | 9.60% | 1.10x | $24.14K |
| Integragen (ALINT) | $691.87K | -367.93% | 7.36x | $431.37K |